Evolutionary genetic dissection of human interferons by Manry, Jérémy et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 208 No. 13  2747-2759
www.jem.org/cgi/doi/10.1084/jem.20111680
2747
IFNs are helicoidal cytokines released by host 
cells in response to the presence of pathogens or 
tumor cells. Human IFNs have been classified 
into three major types on the basis of the cog-
nate receptors through which they signal, gene 
sequence similarity, and chromosomal location 
(Pestka et al., 2004). Type I IFNs include 17 
subtypes  (13  subtypes  of  IFN-  and  IFNs 
///), all of which bind to a receptor com-
posed of two chains, IFNAR1 and IFNAR2 (Uzé 
et al., 2007). The genes encoding type I IFNs 
are intronless and are located in a region span-
ning 400 kb on chromosome 9, with the ex-
ception of IFNK, which is located 6 Mb away 
from the other type I IFN genes (Trent et al., 
1982; Henco et al., 1985; Díaz et al., 1994). 
There is only one type II IFN, IFN-, which 
signals via a receptor composed of the IFN-R1 
and IFN-R2 subunits (Wheelock and Sibley, 
1965; Pestka et al., 2004). The more recently 
described type III IFNs constitute a group of 
three  cytokines,  IL-28A,  IL-28B,  and  IL-29 
(also known as IFN-2, IFN-3, and IFN-1, 
respectively), the genes for which are clustered in 
an 50-kb region of chromosome 19 (Kotenko 
et al., 2003; Sheppard et al., 2003). These IFNs 
activate a signaling pathway similar to that of 
type I IFNs, but act via a different receptor com-
posed of the type III IFN-specific IL-28RA and 
the IL-10RB, the latter subunit being also used 
by the IL-10 and IL-22 receptor (Kotenko et al., 
1997; Xie et al., 2000). There is increasing evi-
dence to suggest that type I and III IFNs have a 
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Interferons (IFNs) are cytokines that play a key role in innate and adaptive immune re-
sponses. Despite the large number of immunological studies of these molecules, the relative 
contributions of the numerous IFNs to human survival remain largely unknown. Here, we 
evaluated the extent to which natural selection has targeted the human IFNs and their 
receptors, to provide insight into the mechanisms that govern host defense in the natural 
setting. We found that some IFN- subtypes, such as IFN-6, IFN-8, IFN-13, and IFN-
14, as well as the type II IFN-, have evolved under strong purifying selection, attesting 
to their essential and nonredundant function in immunity to infection. Conversely, selective 
constraints have been relaxed for other type I IFNs, particularly for IFN-10 and IFN-, 
which have accumulated missense or nonsense mutations at high frequencies within the 
population, suggesting redundancy in host defense. Finally, type III IFNs display geographi-
cally restricted signatures of positive selection in European and Asian populations, indicat-
ing that genetic variation at these genes has conferred a selective advantage to the host, 
most likely by increasing resistance to viral infection. Our population genetic analyses show 
that IFNs differ widely in their biological relevance, and highlight evolutionarily important 
determinants of host immune responsiveness.
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receptor chains by full resequencing in a panel of 186 healthy 
individuals originating from sub-Saharan Africa, Europe, and 
Asia. We sequenced a total of 81.5 kb in each individual—
24% of which corresponded to protein-coding regions, the 
rest comprising noncoding exons, introns, and promoter re-
gions (Table S1)—and identified 1,066 polymorphisms, in-
cluding 988 single-nucleotide polymorphisms (SNPs) and 78 
insertions/deletions  (Table  S2).  This  resequencing  dataset 
was used to estimate several population genetic parameters 
and summary statistics that were, when relevant, compared 
with available genome-wide datasets based on genotyping   
or resequencing. These analyses allowed us to explore the   
effects of natural selection on IFN evolution since the diver-
gence of the human and chimpanzee lineages and within dif-
ferent human populations.
Naturally occurring genetic diversity varies  
between IFNs and populations
We observed remarkable differences in the levels of nucleo-
tide diversity within the population between the genes en-
coding the various IFNs and their receptors and between 
IFN families (Fig. 1 and Table S3). The extremely low level 
of  nucleotide  diversity  observed  for  the  type  II  IFNG, 
which was uniform across populations, contrasted with sev-
eral type I IFNA genes, such as IFNA4, IFNA7, IFNA10, 
IFNA16, IFNA17, and IFNA21, which displayed high lev-
els of diversity (Fig. 1 A). In accordance with the “Out of 
Africa” model (Lewin, 1987) and genome-wide datasets 
(i.e., HapMap and 1,000 Genomes Project; Altshuler et al., 
2010; Durbin et al., 2010), African populations generally 
displayed the highest levels of diversity. However, one third 
of  the  IFN  genes  (mostly  type  I  IFNA  genes:  IFNA4, 
IFNA5, IFNA6, IFNA7, IFNA14, and IFNA17) were most 
diverse in the Asian population, which in turn presented the 
lowest diversity for the three members of the type III IFN 
family (Fig. 1 and Table S3).
Because the type I IFNA genes, as well as the three 
type III IFN genes, display high levels of sequence identity 
and are organized into two distinct clusters of paralogous 
genes (Pestka et al., 2004; Woelk et al., 2007), gene con-
version is likely to have been an important mechanism for 
the evolution of these gene families. Indeed, in multigene 
families, gene conversion among paralogous loci has been 
shown to play an important role in the introduction of ge-
netic variation to each gene (Innan and Kondrashov, 2010; 
Ohta, 2000, 2010). We thus evaluated the extent to which 
gene conversion has contributed to the levels of nucleo-
tide diversity observed at these two groups of IFN genes. 
To do so, we screened highly homologous regions among 
paralogs for the presence of human-specific sites (poly-
morphic or fixed) that have been most likely introduced 
by gene conversion events rather than by point mutations 
(Materials and methods). This analysis allowed us to detect 
a substantial number of putative gene conversion events 
(Table S4), 30 of which corresponded to polymorphic amino 
acid–altering mutations (Table S5). As gene conversion is 
different role from the type II IFN: IFN-/ and IFN- appear 
to have potent antiviral activities, whereas IFN- has anti-
bacterial, antiparisitic, and antifungal properties (Pestka et al., 
2004; Zhang et al., 2008).
In recent years, human genetics studies of both Mende-
lian and complex diseases have identified several variants af-
fecting the production of, or the response to, IFNs, shedding 
light on the genuine functions of IFNs in the natural setting 
(Zhang et al., 2008). Disorders or specific mutations in genes 
involved  in  the  IFN-  circuit,  such  as  in  IFNGR1  and   
IFNGR2, confer a Mendelian predisposition to mycobacte-
rial disease (Filipe-Santos et al., 2006), whereas the disorders 
or specific mutations in patients with impaired type I or type 
III responses are associated with a stronger predisposition 
to viral infections (Dupuis et al., 2003; Chapgier et al., 2006; 
Minegishi et al., 2006). Likewise, mutations affecting type   
I or type III IFN responses have been associated with various 
autoimmune pathologies (Crow et al., 2006a,b; Glocker et al., 
2009; Rice et al., 2009). Several epidemiological genetics 
studies have recently shown that genetic variants in the region 
encompassing the type III IFN IL28B gene are associated 
with the spontaneous clearance of hepatitis C virus (HCV) 
and the response to HCV therapeutic treatment (Ge et al., 2009; 
Suppiah et al., 2009; Tanaka et al., 2009; Thomas et al., 2009).
Our understanding of the mechanisms controlling IFN 
production, the downstream signaling pathways associated 
with these molecules, and their involvement in physiology 
and pathology is starting to be fully appreciated, but several 
biological questions remain unanswered. Given that multiple 
IFN molecules signal through the same receptor (e.g., IFN-
/ and IFN-), are all IFNs equally relevant to host sur-
vival? Are some IFN genes more essential for immunity to 
infection whereas others display immunological redundancy? 
Does IFN-, which is not a prototypic antiviral cytokine, 
have a distinctive evolutionary signature? Has genetic varia-
tion at specific IFN gene loci conferred a selective advantage 
to the host, associated with an increase in resistance to infec-
tious disease? Here, we tackled these questions using an evo-
lutionary genetics approach, which investigates the way in 
which infections have shaped the variability of host defense 
genes by natural selection (Sabeti et al., 2006; Nielsen et al., 
2007; Barreiro and Quintana-Murci, 2010). This approach, 
which has been shown to be an indispensable complement to 
clinical and epidemiological genetics, and to immunological 
studies (Casanova and Abel, 2007; Quintana-Murci et al., 
2007; Casanova et al., 2011), should help to determine the 
biological relevance of IFNs in the setting of a natural ecosys-
tem governed by natural selection.
RESULTS
Full sequencing of genes encoding the human IFNs  
and their receptors
To obtain insight into the selective forces that have driven 
the evolution of the three families of IFNs in humans, we 
characterized the levels of sequence-based diversity in the 21 
genes encoding the IFNs and the 6 genes encoding their JEM Vol. 208, No. 13 
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IFNAR1, IL28A, and IL29, presented high frequencies of 
missense mutations predicted to alter protein function (i.e., 
damaging mutations; Table 1 and Table S3). The most ex-
treme cases were those of IFNA10 and IFNE, for which non-
sense mutations were present in the homozygous state, at high 
frequency, in several populations. For example, one of the 
nonsense mutations of IFNA10 (SNP 60T>A, C20STOP, 
rs10119910), which is located in the signal peptide, abolishes 
the translation of the entire protein. Surprisingly, this stop 
mutation has attained a worldwide frequency of 34%, ranging 
from 18% in Europeans to 54% in Asians. The IFNE nonsense 
mutation  (SNP  211C>T,  Q71STOP,  rs2039381)  decreases 
the length of the protein by two thirds and has attained a 
worldwide frequency of 7%, increasing to 15% in Asia. Such 
high frequencies of nonsynonymous or nonsense mutations 
in some IFN genes may reflect either a relaxation of selective 
constraints caused by the redundancy of the genes concerned, 
or a selective advantage accounted for by the higher frequency 
of functionally advantageous variants.
Purifying selection has operated differently  
among IFN family members
We investigated whether and how natural selection has driven 
the observed heterogeneous patterns of diversity of the vari-
ous  IFNs  and  their 
usually disregarded in population genetics tests, owing to 
the uncertainty associated with the underlying models of 
gene conversion, all variants identified as resulting from gene 
conversion were not considered in the statistical analyses to 
detect natural selection.
Functional diversity is not evenly distributed  
between human IFNs
We identified 245 SNPs in coding regions, including 164 
nonsynonymous and 8 nonsense mutations present in the 
general human population. The occurrence and frequency 
distribution of these variants differed markedly between the 
various IFNs and between populations (Fig. 2, Table 1, and 
Table S3).  IFNs with very low levels of amino acid–altering 
variation are represented by IFNG, in which no nonsynony-
mous mutations were observed, and by a group of type I IFNs 
(IFNA2, IFNA5, IFNA6, IFNA8, IFNA13, IFNA14, IFNA21, 
IFNB1, IFNK, and IFNW1) and the two receptor subunits 
IFNGR1 and IL28RA, which presented nonsynonymous muta-
tions at a low frequency within the population. In contrast, 
we found that 13 genes accumulated nonsynonymous variants   
at very high frequency in the human population (30–100%; 
Fig. 2 and Table 1). Most of these variants were predicted to 
be benign by the PolyPhen algorithm (Adzhubei et al., 
2010), but some genes, such as IFNA10, IFNA16, IFNA17, 
Figure 1.  Patterns of nucleotide diversity for the three families of IFN genes and for the genes encoding their receptors in human popula-
tions. (A) Nucleotide diversity levels for the individual genes in populations representing major ethnic groups. The expected diversity (dotted lines) cor-
responds to the mean diversity levels observed for 20 autosomal noncoding regions in each geographic area (Laval et al., 2010). (B) Comparison of 
nucleotide diversity between IFN families and receptors.
Figure 2.  Proportion of chromosomes  
carrying at least one nonsynonymous or non-
sense variant in the general human popula-
tion. The red portion of the pie charts 
corresponds to the proportion of chromosomes 
carrying at least one nonsynonymous polymor-
phism, the black portion to the proportion of 
chromosomes carrying at least one nonsense 
polymorphism, and the blue portion to the pro-
portion of chromosomes carrying neither non-
synonymous nor nonsense polymorphisms. 
Genes shaded in gray correspond to those encod-
ing the receptor subunits of each IFN family.2750 Natural selection of human interferons | Manry et al.
IFNA6, IFNA13, and IFNA14, whereas no gene conversion 
events were detected at IFNA8 (Table S5). Our simulation 
analyses showed that the removal of gene conversion–derived 
events cannot produce spurious signals of purifying selection 
(Fig. S1). However, because of the minimal, but nonnull, 
uncertainty in our procedure for gene conversion detection, 
IFNA8 represents the most robust target of purifying selection 
among type I IFNs. At the other extreme, IL28B was the only 
gene that had a  value significantly greater than 1, consistent 
with the action of positive selection.
Positive selection has targeted type III IFNs  
in non-African populations
We next investigated the ways in which positive selection has 
affected IFN genes in a population-specific manner, as popula-
tions from different continents have clearly been historically 
exposed to different selection pressures (Novembre and Di 
Rienzo, 2009). We performed various intraspecies neutrality 
tests on various aspects of the data, including the allele frequency 
receptors by first estimating the direction and strength of   
selection within the human species as a whole. To this end, we 
measured dS and dN, i.e., the number of silent and nonsynony-
mous fixed differences between humans and chimpanzees, 
together with pS and pN, i.e., the number of silent and non-
synonymous polymorphic sites observed within humans. We 
used the McDonald-Kreitman Poisson random field method 
(Sawyer and Hartl, 1992; Bustamante et al., 2005) to estimate 
 (i.e.,   N/S, where N and S are estimates of the rate 
of nonsynonymous and silent mutations) and to assess the se-
lection pressure driving amino acid substitutions. Under neu-
trality,  is not significantly different from 1. Values <1 indicate 
a deficit of nonsynonymous variants, whereas values >1 reflect 
an excess of amino acid changes. We found that only IFNA6, 
IFNA8, IFNA13 and IFNA14, and IFNG had  values signif-
icantly <1, consistent with their evolution under the strongest 
purifying selection (Fig. 3). Among type I IFNs, we removed 
from  our  analyses  a  few  low-frequency  nonsynonymous 
mutations that were found to result from gene conversion at 
Table 1.  Coding variation at IFN genes and their receptors in human populations
Number of polymorphismsa Highest derived allele frequencyb Proportion of chromosomesc
Gene Silent Sites NS Sites NS PRD STOP NS PRD STOP NS PRD STOP
IFNA1 1835 440 5 1 0 94.62 0.27 0 97.85 0.27 0
IFNA2 2030 438 3 0 0 1.08 0 0 2.69 0 0
IFNA4 1839 439 10 1 0 99.73 0.27 0 100.00 0.27 0
IFNA5 1300 443 4 3 1 0.54 0.54 0.27 2.96 1.08 0.27
IFNA6 1464 441 3 1 0 0.54 0.27 0 0.81 0.27 0
IFNA7 1285 441 5 0 0 99.46 0 0 99.46 0 0
IFNA8 1889 440 1 0 0 7.26 0 0 7.26 0 0
IFNA10 1644 438 13 0 3 98.12 0 34.14 100.00 0 34.68
IFNA13 1461 440 3 0 0 5.11 0 0 6.99 0 0
IFNA14 1216 448 2 0 1 0.54 0 0.27 0.81 0 0
IFNA16 1700 439 7 1 0 97.58 97.04 0 100.00 97.04 0
IFNA17 1710 438 6 1 0 65.86 65.86 0 98.39 65.86 0
IFNA21 1801 440 9 1 1 4.03 0.27 0.27 8.87 0.27 0.27
IFNB1 1520 439 5 1 0 1.61 0.27 0 3.23 0.27 0
IFNE 2156 490 3 1 1 2.15 0.27 7.26 3.49 0.27 7.26
IFNK 2186 496 4 3 0 6.99 2.69 0 10.75 3.76 0
IFNW1 2151 451 6 5 0 4.30 4.30 0 5.91 5.65 0
IFNAR1 5250 1303 9 1 0 20.43 0.27 0 29.30 0.27 0
IFNAR2 5737 1201 10 5 0 58.87 0.81 0 74.19 2.42 0
IFNG 4172 395 0 0 0 0 0 0 0 0 0
IFNGR1 4345 1130 10 2 0 1.87 0.27 0 5.65 0.54 0
IFNGR2 4015 715 6 1 0 76.33 0.27 0 77.15 0.27 0
IL28A 1325 303 8 1 1 92.74 80.11 0.27 100.00 80.11 0.27
IL28B 3031 434 12 3 0 62.63 3.49 0 65.59 3.76 0
IL29 1558 443 5 1 0 70.16 70.16 0 73.12 70.16 0
IL28RA 3295 1177 10 4 0 3.76 3.76 0 11.29 4.84 0
IL10RB 3696 721 5 1 0 32.53 0.54 0 34.41 0.54 0
aAbsolute numbers of polymorphisms observed in our entire dataset
bAmong the different variants observed in each category, the value (in %) of the most frequent polymorphism is shown
cProportion of chromosomes (in %) in the general population carrying at least one nonsynonymous or nonsense variant. NS stands for nonsynonymous. “PRD” refers to 
“probably damaging” mutations as predicted by PolyPhen v2 HumDiv.JEM Vol. 208, No. 13 
Article
2751
genomic regions sequenced in a set of 
populations similar to those used in this 
study (Voight et al., 2005; Laval et al., 
2010). For the population differentiation 
tests, we obtained a background expecta-
tion of genome-wide FST by analyzing the 
publicly available HGDP-CEPH dataset (Li et al., 2008) from 
the same set of individuals we sequenced in this study. In addi-
tion, we complemented our analyses of recent positive selec-
tion by obtaining the iHS values for each SNP in the populations 
of the HapMap Phase II dataset (Frazer et al., 2007).
We defined genes under selection conservatively as those 
(a) for which significant results were obtained after both de-
mographic corrections or for which results were significant at 
the genome-wide level, and (b) for which significant results 
were obtained in at least two tests of selection based on dif-
ferent aspects of the data (e.g., allele frequency spectrum tests 
and FST) in the same population. With these stringent 
criteria, most type I IFNs and the type II IFN did not 
show compelling signatures of selection in any of the 
continental populations here studied. In contrast, we 
found that positive selection had strongly affected the 
members of the type III IFN family in European and 
Asian populations (Fig. 4, Fig. 5, and Table 2). In 
addition, the results of the neutrality tests for type III 
IFNs remained significant after correction for multi-
ple testing, emphasizing the intensity of the events of 
spectrum (i.e., Tajima’s D, Fu and Li’s D* and F    *, and Fay and 
Wu’s H tests), levels of population differentiation (i.e., FST), 
and haplotype-based tests (i.e., derived intrallelic nucleotide 
diversity [DIND] and integrated haplotype score [iHS] tests; 
Kreitman, 2000; Nielsen et al., 2007). As most of these tests are 
known to be sensitive to the effects of demography and selec-
tion, we used simulation-based or empirical procedures to 
correct for the influence of demography on the patterns of 
population genetic diversity. For the allele frequency spectrum 
and DIND tests, we incorporated into our neutral expecta-
tions two demographic models based on multiple, noncoding 
Figure 3.  Estimation of the intensity of nat-
ural selection acting on the various IFN fami-
lies and their receptors. The strength of natural 
selection was assessed by estimating  values. 
Under neutrality,  is not significantly different 
from 1. Values below 1 are consistent with selec-
tion against nonsynonymous variants, whereas 
values greater than 1 indicate an excess of amino 
acid changes. Bars indicate 95% Bayesian confi-
dence intervals, and red circles indicate genes 
with  estimates significantly above or below 1. 
Genes shaded in gray correspond to those encod-
ing the receptor subunits of each IFN family.
Figure 4.  Detection of positive selection in Asia using the 
DIND test. We plotted iA/iD values against derived allele fre-
quencies (DAFs). P-values were obtained by comparing the  
iA/iD values for the three type III IFN genes against the expected 
iA/iD values obtained in 104 simulations, taking into account 
the most conservative demographic model (Laval et al., 2010). 
The top dashed line on the graph corresponds to the 99th per-
centile, and the bottom to the 95th percentile. Dots above the 
95th percentile dashed line correspond to mutations that have 
increased in frequency faster than expected under neutrality in 
the Asian population. These mutations have been most likely 
targeted by positive selection, and thus conferred an advantage 
to the host. Red and black dots correspond to nonsynonymous 
and silent polymorphisms, respectively. For DIND analyses con-
cerning all genes encoding the 27 IFNs and their receptors in all 
populations, see Fig. S3.2752 Natural selection of human interferons | Manry et al.
largest allele frequency differences among populations in the 
1,000 Genomes project (Durbin et al., 2010). In addition, 
this nonsynonymous variant gave a significant result for the 
DIND test in Asian populations (iA/iD = 3.71, P < 0.01; 
Fig. 4) and gave a significant iHS value of -2.285 in Europe-
ans from the HapMap Phase II dataset (iHS was not calcu-
lated for Asian HapMap populations, because this SNP has a 
frequency >95%). These results suggest that IL29 variation, 
and the D188N variant in particular, has conferred a selective 
advantage to Eurasian populations.
DISCUSSION
In this study, we demonstrate that the different IFN families, 
and their individual members, have followed different evolu-
tionary trajectories in humans. First, we found that type I 
IFN subtypes differ in their levels of evolutionary constraint. 
Amino acid–altering variation has been constrained for some 
type I IFNs, with IFNA6, IFNA8, IFNA13, and IFNA14 
found to have been subject to the strongest purifying selec-
tion (Fig. 3). Low levels of amino acid–altering variation 
were  also  observed  at  IFNA2,  IFNA5,  IFNA21,  IFNB1, 
IFNK, and IFNW1 (Fig. 2 and Table 1). Conversely, selec-
tive constraints have been relaxed for other type I IFNs, which 
harbor  nonsynonymous  variants  at  high  population  fre-
quencies (IFNA1, IFNA4, IFNA7, IFNA10, IFNA16, and 
IFNA17). Furthermore, some IFNs present nonsense muta-
tions in the homozygous state (IFNA10 and IFNE), suggesting 
that they might be currently undergoing pseudogenization. 
We also found that some nonsynonymous polymorphisms at 
several IFNA genes, for the most part observed at low popu-
lation frequencies, appear to have been introduced by gene 
conversion from their paralogs (Table S5). This observation 
supports the notion that, besides gene duplication, gene con-
version has contributed to the evolution of type I IFNs in 
mammals (Hughes, 1995; Woelk et al., 2007; Génin et al., 
2009b). Together, the strong constraints characterizing some 
type I IFNs suggest that they fulfill an essential, nonredundant 
positive selection detected. The three type III IFN genes are 
adjacent to each other on an 50-kb region of chromosome 
19 (Fig. 6), but they nonetheless displayed low levels of link-
age disequilibrium in all populations (Fig. S2). This suggests 
that independent positive selection events have targeted 
IL28A, IL28B, and IL29.
IL28A and IL28B deviated significantly from neutral ex-
pectations in the Asian population, in allele frequency spec-
trum tests (Table 2). Furthermore, the derived alleles of two 
SNPs in IL28A and five in IL28B were found to be associ-
ated with significantly lower levels of surrounding nucleotide 
diversity, given their high population frequency (>90%), in 
Asia (see the DIND test in Fig. 4). Interestingly, the two 
SNPs in IL28A and one in IL28B correspond to amino acid–
altering variants (IL28A SNP 983G>A, A112T, rs8103362; 
IL28A SNP 1227C>T, H160Y, rs61735713; IL28B SNP 
502G>A, R70K, rs8103142). These amino acid changes there-
fore  appear  to  have  increased  in  frequency  more  rapidly 
than would be expected under neutrality, in the Asian popu-
lation, consistent with the action of population-specific posi-
tive selection.
We also detected strong signals of positive selection at the 
IL29 locus. First, allele frequency spectrum tests detected a 
significant  excess  of  rare  variants  in  both  Europeans  and 
Asians (Table 2). Second, very high levels of population dif-
ferentiation were observed at the IL29 locus between African 
and Eurasian populations (mean FST = 0.42). In particular, 
the  nonsynonymous  variant  2054G>A  (D188N,  rs30461, 
predicted to be probably damaging by PolyPhen), presented 
extreme levels of differentiation between Africans and Eur-
asians (FST Africa/Asia = 0.71, P = 0.014; FST Africa/Europe = 
0.66, P = 0.025, using the HGDP-CEPH dataset; Fig. 5). 
Remarkably, this SNP not only presented the highest degree 
of population differentiation of all SNPs in our dataset but 
was also among the most highly differentiated SNPs at the level 
of the entire human genome. Indeed, the D188N variant falls 
into the group of 139 nonsynonymous SNPs presenting the 
Figure 5.  Detection of positive selection on the basis of levels of population differentiation. Population pairwise FST values are plotted against 
expected heterozygosity for all the SNPs identified in our study for Africans versus Europeans (A), Africans versus Asians (B), and Europeans versus Asians 
(C). The dashed lines represent the 99th and 95th percentiles of the HGDP-CEPH genotyping dataset for the same individuals (represented by the density 
area in blue; Li et al., 2008). Black dots correspond to silent polymorphisms and red dots correspond to nonsynonymous polymorphisms.JEM Vol. 208, No. 13 
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in natural conditions. A greater tolerance for the increase in 
frequency of missense or nonsense mutations in the general 
population is observed in another set of type I IFNs, suggest-
ing that the functions they fulfill are largely overlapping with 
other IFN subtypes. The existence of multiple type I IFNs 
and differences in their degrees of diversity and redundancy 
may attest to the great capacity of this host defense system to 
evolve, to develop efficient antiviral responses.
However, there is a growing body of work showing that 
type I IFN activity can also be detrimental to the host (Decker 
et al., 2005; Vilcek, 2006; Trinchieri, 2010). Experimental data 
from mice and clinical observations in human patients have 
shown that IFN production can be harmful in the context of 
infection and can increase morbidity (Gresser et al., 1975; 
Rivière et al., 1977; Vilcek, 1984). Such adverse effects of in-
creased IFN production, such as systemic lupus erythematosus 
function in host defense. In contrast, the high population fre-
quencies of missense or nonsense mutations, occurring through 
mutation or gene conversion, found in other type I IFN sub-
types, suggest that these molecules are highly redundant.
Our findings provide evolutionary evidence of the com-
plexity of the biological actions of type I IFNs. Indeed, in the 
mouse model, they play a key role in protective antiviral im-
munity to multiple experimental infections (Jouanguy et al., 
2007; Vilcek, 2006). In humans, primary immunodeficien-
cies of the type I IFN pathway, including STAT-1 and TYK-2 
deficiencies, have also shown that type I IFNs are critical 
for antiviral immunity (Dupuis et al., 2003; Chapgier et al., 
2006, 2009; Minegishi et al., 2006; Zhang et al., 2008). The 
integration of our population genetics data into a clinical 
framework thus indicates that at least one subgroup of type I 
IFNs plays a critical, nonredundant role in antiviral immunity 
Table 2.  Sequence-based neutrality tests across the 27 genes encoding the IFNs and their receptors
AFRICA EUROPE ASIA
Gene TD D F Hn TD D F Hn TD D F Hn
TYPE I IFNs
IFNA1 0.15 0.09 0.00 1.06 1.59† 0.82 1.31 3.20* 0.97 0.65 0.91 3.07*
IFNA2 1.42 0.01 0.64 0.94 0.02 0.41 0.31 0.90 0.54 0.12 0.31 0.20
IFNA4 0.88 1.57 1.56 0.69 0.28 0.97 0.61 2.59* 1.24 0.68 0.04 0.43
IFNA5 0.93 0.65 0.89 0.06 1.09 2.42† 2.33*† 0.66 0.19 0.42 0.25 0.40
IFNA6 0.92 0.28 0.16 0.60 0.22 0.31 0.33 0.67 0.31 0.07 0.07 0.45
IFNA7 1.78 1.55 1.94 0.96 1.32 1.55 1.74 0.27 0.58 0.12 0.14 1.14
IFNA8 0.47 0.11 0.29 0.72 0.72 2.21† 1.99 0.47 0.33 0.49 0.52 0.85
IFNA10 0.39 1.11 0.62 1.81* 1.20 0.59 0.98 1.95 0.86 1.59 0.83 0.41
IFNA13 0.10 1.36*† 1.09*† 0.35 0.63 0.65 0.77 1.00 0.17 3.01*† 2.38*† 0.09
IFNA14 1.70 1.80 2.10 0.66 1.37 2.83*† 2.77*† 0.94 0.68 0.31 0.01 0.28
IFNA16 1.14 0.33 0.31 3.40* 0.96 1.28 0.51 4.75**† 0.67 0.27 0.49 0.06
IFNA17 0.21 0.68*† 0.60† 0.64 0.06 0.68 0.53 1.50 1.51 0.82 0.07 0.27
IFNA21 1.12 2.37 2.28 0.16 0.62 0.28 0.47 0.42 0.51 0.41 0.53 0.30
IFNB1 1.38 1.06 1.41 -0.79 0.28 1.25 1.09 1.00 0.08 0.42 0.36 0.65
IFNE 0.51 0.35 0.49 0.69 0.29 0.42 0.45 0.03 0.19 1.02 0.71 0.08
IFNK 0.89 0.65 0.89 0.08 0.90 1.52 1.54 0.53 0.84 3.25*† 2.81*† 0.99
IFNW1 1.07 1.14 1.33 0.61 1.36 3.45**† 3.20** 0.36 0.33 0.82 0.77 0.76
IFNAR1 0.82 0.77 0.95 -0.27 0.46 0.43 0.11 1.10 0.05 3.50**† 2.66*† 0.75
IFNAR2 0.99 2.58 2.31 -0.71 1.03 0.39 0.19 0.10 0.01 1.76 1.28 0.94
TYPE II IFN
IFNG 1.60 1.39 1.76 -2.10* 0.34 1.02 0.65 0.42 0.70 0.12 0.37 0.11
IFNGR1 1.44 2.13 2.23 -0.26 0.27 2.02 1.43 0.44 0.37 0.95 -0.88 0.55
IFNGR2 1.13 3.09 2.77 -0.37 0.39 1.63 1.05 0.54 0.73 4.08**† 3.36**† 0.92
TYPE III IFNs
IL28A 0.95 1.99 1.90 -2.50 0.93 1.33 1.42 0.05 1.92*†† 3.39**† 3.42**† 0.89
IL28B 0.18 1.18**† 0.75† 0.42 0.66 1.06 0.48 1.73 1.57*† 3.01*† 2.94*† 2.35*
IL29 1.00 2.00 1.95 -0.33 1.72*† 3.81**†† 3.68**†† 1.41 1.71*†† 0.86 1.36 1.56
IL28RA 0.64 0.93 0.97 -0.24 0.20 1.52 1.22 0.28 -0.83 2.63*† 2.33*† 0.19
IL10RB 0.32 0.63 0.60 0.66 1.50 0.55 0.26 0.28 0.53 1.32 0.74 0.35
TD, Tajima’s D; D, Fu & Li’s D*; F, Fu & Li’s F  *; Hn, normalized Fay & Wu’s H. **/*, P ≤ 0.01 and ≤ 0.05, respectively, according to the model of (Voight et al., 2005); ††/†,  
P ≤ 0.01 and ≤ 0.05, respectively, according to the model of (Laval et al., 2010). 2754 Natural selection of human interferons | Manry et al.
display a complete absence of amino acid–altering mutations. 
This gene was subject to the strongest purifying selection of 
all IFNs, and we previously showed that IFNG is among the 
10% of immune-related genes subject to the most intense 
selective constraints on amino acid variation in humans (Manry 
et al., 2011). Clinical genetic studies have demonstrated that 
six genes involved in the IFN- circuit (IL-12/23–IFN-) 
play a critical role in protective immunity (Filipe-Santos et al., 
2006).  Specifically,  disorders  of  IFN-  production  caused   
by mutations affecting IL-12B, IL-12RB1, or specific NEMO 
mutations, and impaired IFN- responses caused by IFNGR1, 
IFNGR2, or specific STAT1 mutations, are associated with 
Mendelian susceptibility to mycobacterial disease in patients 
resistant to most viruses (Zhang et al., 2008). Population and 
clinical data show that no variation with a significant impact 
on protein function is tolerated at loci involved in IFN-–
mediated immunity, indicating that the IFN- pathway is   
essential and nonredundant in host survival, including host 
defense against mycobacteria.
Finally, our data showed that type III IFNs are the only 
group of IFNs where selective pressures have involved pro-
cesses of geographically restricted adaptation, revealing that 
genetic variation at these genes has conferred a selective ad-
vantage to specific human populations (Fig. 6). There is in-
creasing evidence from clinical genetic studies to support a 
major role of these molecules in antiviral immunity (Zhang 
et al., 2008), so the selection pressure acting on type III IFN 
genes may be of viral origin. Strong support for this notion 
has been provided by recent genome-wide association stud-
ies. Indeed, the five IL28B polymorphisms we identified as 
being under positive selection in Asia have been associated 
with the spontaneous clearance of HCV and a better response 
to pegylated IFN-ribavirin treatment for chronic HCV in-
fection in populations of African, European, and Asian ances-
try (Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009; 
Thomas et al., 2009; Rauch et al., 2010). These SNPs include 
two located in the regulatory region of IL28B (SNP -3180A>G, 
(Banchereau et al., 2004; Crow, 2007; Le Bon et al., 2006a; 
Le Bon et al., 2006b), have also been observed in the context 
of autoimmune diseases (Crow et al., 2003; Banchereau and 
Pascual, 2006). In addition, there is increasing evidence to 
suggest that type I IFNs have opposing roles in viral and bac-
terial infection (Decker et al., 2005; Vilcek, 2006; Trinchieri, 
2010). Such a multifaceted mechanism of host defense is il-
lustrated by IFN-8 and IFN-13, which are both under 
strong selective constraint yet display high and low antiviral 
potency, respectively (Foster et al., 1996; Foster and Finter, 
1998; Koyama et al., 2006; Jaks et al., 2007; Lavoie et al., 2011). 
However, differences in bioactivity between IFN subtypes will 
depend not only on their respective potencies and distinct 
receptor-binding chemistries, as recently shown for a subset 
of type I IFNs (Thomas et al., 2011), but also on their indi-
vidual production. Few studies have systematically assessed 
the levels of expression of the multiple type I IFNs (Coccia et al., 
2004; Génin et al., 2009a) and, because of the differences in 
experimental conditions used, there is as yet no clear consen-
sus as to which subtypes are the most expressed in different 
cell types. In light of this, we hypothesize that type I IFNs 
presenting various antiviral potencies and/or production could 
have been maintained, and selected for, to regulate global 
type I IFN activity. To test this hypothesis, further analyses are 
needed to (a) characterize the expression and potency of the 
individual type I IFN subtypes under different conditions of 
infection and in different cell types, in particular for those 
exhibiting  the  strongest  signatures  of  purifying  selection;   
(b) define how the variation in both production and potency 
of the various subtypes is under genetic control (i.e., host ge-
netic variation in both protein-coding regions and regulatory 
regions); and (c) evaluate how the combination of the whole 
set of type I IFN subtypes, with their varying functional di-
versity, affects downstream transcriptional programs and host 
responses at the organism level.
Second, we found that the type II IFNG was the only gene, 
across all three families of human IFNs and their receptors, to 
Figure 6.  Spatial distribution of positively selected variants across type III IFN genes. Genomic organization of the three members of the type III 
IFN family, IL28B, IL28A, and IL29. Filled boxes correspond to exonic regions, and arrows above exons indicate the direction of the open reading frame. 
Genetic variants displaying signatures of population-specific positive selection are shown; noncoding SNPs are indicated in black and amino acid changes 
in red. At the gene level, IL28A and IL28B displayed signatures of positive selection in Asia, and IL29 in both Europe and Asia (Table 2). At the SNP level, 
the action of positive selection targeting the five SNPs at IL28B and the two at IL28A was supported by the DIND test (Fig. 4), whereas that at the IL29 
D188N variant was supported by the DIND test and iHS, as well as by the levels of population differentiation (Fig. 5).JEM Vol. 208, No. 13 
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use of population genetics in the context of infection, with a 
view to improving our understanding of the biological im-
portance of immunity-related genes in host defense in the 
natural setting.
MATERIALS AND METHODS
Population samples. Sequence variation for all human IFNs and their re-
ceptors was determined in 186 individuals from sub-Saharan Africa, Europe, 
and Asia (62 individuals per geographic region) from the HGDP-CEPH 
panel (Cann et al., 2002). Sub-Saharan African populations were composed 
of 19 Bantu from Kenya, 21 Mandenka from Senegal, and 22 Yoruba from 
Nigeria; European populations were composed of 20 French, 14 Italians, 
6 Orcadians, and 22 Russians; the Asian populations were composed of 15 
Han Chinese and 33 individuals from Chinese minorities, 10 Japanese, and 
4 Cambodians. Population structure within continental regions has been 
shown to be limited (Li et al., 2008) and to have a negligible influence 
on the inference of natural selection (Manry et al., 2011). This study was 
approved by the Institut Pasteur Institutional Review Board (no. RBM 
2008.06).
DNA sequencing. We sequenced the 27 genes encoding the IFNs and 
their receptors using Sanger sequencing. Given the extremely high sequence 
identity among IFN genes (i.e., the type I IFNA genes and type III IFN 
genes, are organized into two distinct clusters of paralogous genes), Sanger 
sequencing was the most appropriate choice to differentiate with confidence 
regions that are highly paralogous. Another advantage of Sanger sequencing 
is the reliable detection of low-frequency variants, which are the substrate 
used to detect and estimate the intensity of purifying selection. This contrasts 
with publicly available whole genome sequence datasets that, even if they 
include IFNs (e.g., 1,000 Genomes), are depleted for low-frequency vari-
ants, particularly nonsynonymous mutations (Durbin et al., 2010), because of 
the low coverage at which the genomes have been sequenced. For each 
gene, we sequenced all the exon regions and at least as much of the nonexon 
regions, including intron, 5, and 3 regions (Table S1). All sequences were 
obtained with the Big Dye Terminator kit and a 3730 XL automated   
sequencer  from  Applied  Biosystems.  Sequence  files  and  chromatograms 
were inspected with GENALYS software (Takahashi et al., 2003). All single-
tons or ambiguous polymorphisms were systematically reamplified and re-
sequenced. We were unable to resequence the first exon of IFNGR2 and the 
first exon of IL10RB for technical reasons, probably because of the very high 
GC content of the region (73 and 72%, respectively). The reference sequences 
used are given in Table S1.
Gene conversion analyses. Because interlocus gene conversion requires 
high levels of sequence identity between loci (Mansai and Innan, 2010), we 
sought to detect gene conversion events based on (a) the local homology 
observed between two paralogs and (b) the ancestral/derived state of each 
base pair in humans determined using the corresponding chimpanzee ortho-
logue. For a pair of genes, X and Y, resequenced in two different individuals, 
each sequence was subdivided in fragments of 40 bp. Each fragment defined 
in gene X was compared with all the possible fragments in gene Y, irrespec-
tive of their location. This procedure was performed for all pairs of individu-
als in our sample (n = 186). We retained pairs of fragments with a sequence 
identity >90%. Within these pairs, a mutation observed at a given position 
in gene X was declared as being a putative gene conversion event when its 
derived state (fixed or polymorphic) was equal to the ancestral or derived 
state observed at the same position in gene Y. However, situations that could 
be most parsimoniously explained by a single point mutation (i.e., a muta-
tion fixed for the derived state in gene X and fixed for the ancestral allele at 
the same position in gene Y) were not considered as a conversion event. For 
each gene, this method provided a set of mutations probably resulting from 
gene conversion. We declared the putative acceptor and donor genes on the 
basis of the frequencies of converted mutations (i.e., the donor has the high-
est frequency of the conversion event).
rs12979860; and SNP -37C>G, rs28416813), one in an in-
tron (SNP 685C>T rs11881222), one in the 3 region (SNP 
1388T>G, rs4803217), and one nonsynonymous SNP of 
IL28B  (SNP  502G>A,  R70K,  rs8103142).  Interestingly, 
based on the odds ratios for protective alleles, it has been 
suggested that variation of the IL28B gene may confer a 
stronger protective effect in Asians than in individuals of 
European or African ancestry (O’Brien, 2009). However, the 
environmental, genetic, and evolutionary factors underlying 
this difference remain unknown.
Our data provide new insight into the relationship be-
tween  type  III  IFN  variation  and  ethnic  background  by 
showing  that  Asian  populations  have  evolved  the  most 
adaptively and protective alleles have increased in frequency 
among Asians as a result of positive selection, rather than 
simple genetic drift. Given the chronic and insidious nature 
of HCV pathogenesis, it is unlikely that HCV, at least in its 
modern form, is really responsible for the selection pres-
sure exerted on IL28B. In light of this, we hypothesize that 
other ancestral and more virulent flaviviruses are responsi-
ble for the selective footprints observed. To this end, it will 
be instructive to determine whether IL28B polymorphisms 
are associated with natural immunity to related viruses (e.g., 
hemorrhagic flaviviruses and/or encephalogenic alphaviruses).
The overlap between the IL28B variants found here to 
be  under  positive  selection  and  those  associated  with  the 
spontaneous clearance of HCV infection provides an impor-
tant proof-of-concept for the value of the evolutionary 
approach, as a complement to epidemiological and medical 
genetics studies. This is particularly important for positively 
selected IL28A and IL29 variants, whose function is not yet 
fully appreciated. The strongest signature of positive selection 
we  observed  concerned  a  nonsynonymous  SNP  in  IL29 
(SNP 2054G>A, D188N, rs30461) in European and Asian 
populations. However, the way in which this variant confers 
a selective advantage to the host and the pathogens responsi-
ble for exerting a selective pressure on IL29 remains to be 
identified. Because the three type III IFNs operate as inde-
pendent genetic entities, we propose that the signatures of 
positive selection, which appear to be independent, displayed 
by each type III IFN reflect their different relative contribu-
tions to human fitness and survival. Additional studies are re-
quired to unravel the immunological role and phenotypic 
expression of type III IFN subtypes, particularly polymor-
phisms shown to be under positive selection, in relation to 
susceptibility to, or the pathogenesis of infectious diseases or 
autoimmune disorders.
In conclusion, our population genetics data indicate that 
the various members of the human IFN families differ in bio-
logical relevance, ranging from highly constrained to redun-
dant and expendable. The identification of individual IFN 
genes subject to strong constraints or to adaptive evolution, 
attesting to their important role in immunity to infection, 
paves the way for additional studies to evaluate the potential 
of these molecules for use in vaccination, diagnosis, and treat-
ment. More generally, our study provides a paradigm of the 2756 Natural selection of human interferons | Manry et al.
events, we used the DIND test, based on the iA/iD ratio, where iA and 
iD are the levels of nucleotide diversity associated with the haplotypes car-
rying the ancestral and the derived alleles, respectively (Barreiro et al., 2009). 
This test is based on the rationale that a derived allele under positive selec-
tion present at high frequency in the population should display lower levels 
of nucleotide diversity at linked sites than expected, and therefore higher 
than expected a iA/iD ratio. Singletons and doubletons were excluded 
from this analysis. To define statistical significance, the iA/iD values esti-
mated for all IFNs and their receptors were compared against a background 
distribution obtained by means of 104 simulations of the genomic regions 
concerned, conditional on the number of segregating sites and the recombi-
nation rate of the regions, and integrating the demographic models previ-
ously described (Voight et al., 2005; Laval et al., 2010). We also used tests 
based on levels of extended haplotype homozygosity, such as the iHS (Voight 
et al., 2006). These tests share a similar rationale: an allele that has a high 
population frequency and that is associated with an unusually long-range 
haplotype as compared with genome-wide expectations is likely to have 
been targeted by recent positive selection. This is explained by the rapid in-
crease in allele frequency of the advantageous allele, meaning that recombi-
nation will not have enough time to substantially break down the haplotype 
on which the selected mutation arose (Nielsen et al., 2007). We assessed the 
levels of population differentiation for the entire SNP panel, using the FST 
statistics derived from the analysis of variance (Excoffier et al., 1992). We 
identified SNPs presenting extreme levels of population differentiation, a 
signature of positive selection (Sabeti et al., 2006; Nielsen et al., 2007; 
Barreiro et al., 2008) by comparing the observed FST values for individual 
SNPs in the genes studied here with a genome-wide FST distribution. This 
was calculated using 640,000 SNPs genotyped in the same subset of indi-
viduals from the HGDP-CEPH dataset (Li et al., 2008), with the exception 
of five individuals who were not genotyped. Because FST values depend on 
allele frequencies, FST comparisons were confined to SNPs presenting similar 
allele frequencies (i.e., similar expected heterozygosities). Empirical p-values 
for each SNP in the 27 genes were estimated as previously described 
(Barreiro et al., 2009). As the genome-wide FST distribution of the HGDP-
CEPH dataset, used here to represent the neutral distribution, includes loci 
targeted by positive selection (Pickrell et al., 2009), the comparison of FST 
values of IFNs against this distribution represents a highly conservative ap-
proach to detecting selection. We defined genes under selection conserva-
tively as those (a) for which significant results were obtained after both 
demographic corrections or for which results are significant at the genome-
wide level, and (b) for which significant results were obtained in at least 
two tests of selection based on different aspects of the data (e.g., allele fre-
quency spectrum tests and FST) in the same population. To test the robustness 
of our results, and to prevent the detection of false positive signatures of pos-
itive selection, we measured the probability, within and between the genes 
in our dataset, of observing neutral simulations exhibiting “significant” results. 
Specifically, we calculated the number of simulations that exhibit at least two 
significant tests among Tajima’s D, DIND test, and FST for each gene given 
the observed p-values, and corrected by the number of genes in our dataset 
(27 genes). The functional impact of all amino acid–altering mutations 
(benign, possibly damaging, or probably damaging) was predicted with the 
Polyphen algorithm v2 HumDiv (Adzhubei et al., 2010). This method, 
which takes into account protein structure and/or sequence conservation 
information for each gene, has been shown to be the best predictor of the 
fitness effects of amino acid substitutions (Williamson et al., 2005).
Online  supplemental  material. Fig. S1 shows the simulations of our 
method to detect gene conversion events and the impact of their removal 
on the detection of selection. Fig. S2 shows the levels of linkage disequi-
librium in the genomic region encompassing the three type III IFN genes. 
Fig. S3 shows the DIND analyses for all genes encoding the IFNs and their 
receptors in all populations. Table S1 provides details of the resequenced 
regions for the genes encoding the IFNs and their receptors. Table S2 
lists all exonic SNPs detected at the IFN genes and their receptors. Table S3 
shows the diversity indices across the genes encoding the IFNs and their 
We  evaluated  the  power  of  the  method  to  detect  gene  conversion 
events and the influence of their removal on the detection of selection by 
means of coalescence simulations, using SIMCOAL v2 (Laval and Excoffier, 
2004). We simulated two duplicated genes in the human and chimpanzee 
lineages, with the gene duplication predating the divergence of the two spe-
cies. 20 human sequences (10 individuals) and 1 chimpanzee sequence were 
simulated with the following parameters: the recombination rate expected in 
humans (1cM/Mb), a human/chimpanzee divergence time of 5 million years, 
constant population sizes (n = 1,000 individuals), and a mutation rate ad-
justed to the number of mutations observed in our dataset. The two dupli-
cated genes, each 2,000 bp long, were simulated using a global sequence 
identity between paralogs set to be equal to 90%. In addition, 30% of sites 
were set to be nonsynonymous, with a sequence identity set to be equal to 
95% in coding regions. When gene conversion was introduced, a fixed num-
ber of conversion events were simulated using a tract length set at 100 bp 
(consistent with empirical estimates of mean tract length (Mansai and Innan, 
2010)). We allowed conversion when sequence identity between tracts was 
>60%, specifying that 90% of the conversion events simulated involved a 
sequence identity >90%. Next, all mutations present in the tract of the donor 
gene (both fixed and polymorphic within the human lineage) were copied 
in the acceptor gene. To evaluate the impact of gene conversion in a more 
realistic scenario, we also introduced purifying selection on nonsynonymous 
sites by using a lower mutation rate at nonsynonymous sites with respect to 
silent sites. We then applied our method of gene conversion detection and 
calculated the power to detect the gene conversion events and the false dis-
covery rate (Fig. S1).
All variants identified as resulting from gene conversion were not con-
sidered in the statistical analyses to detect selection. It should be noted that 
ignoring the events most parsimoniously explained by a point mutation (i.e., 
fixed mutations in humans) will have no effect on the detection of selection 
using analyses based on intraspecies polymorphism, and cannot generate 
false-positive signals of purifying selection using interspecies tests corrected 
for gene conversion (Fig. S1). In addition, we verified manually if some of 
the amino acid–altering polymorphisms detected as resulting from gene con-
version could be ambiguously explained by gene conversion or mutation, 
because the erroneous removal of such sites can create spurious signals of 
purifying selection. Two events were identified as false positives, in IFNA10 
and IFNA17, and the corresponding mutations were thus not excluded from 
our analyses.
Statistical analyses. We used Haploview software (Barrett et al., 2005) to 
obtain and visualize levels of linkage disequilibrium in the various genomic 
regions. Haplotype reconstruction was performed by the Bayesian method, 
implemented in Phase (v.2.1.1; Stephens and Donnelly, 2003). We applied 
the  algorithm  five  times,  using  different  randomly  generated  seeds,  and 
checked the consistency of the results across runs. The entire dataset was 
used for the calculation of sequence-based neutrality statistics, including 
Tajima’s D, Fu & Li’s D*, Fu & Li’s F*, Fay & Wu’s H, in DnaSP v5.1 
(Rozas et al., 2003). P-values for the various neutrality tests were estimated 
from 104 coalescent simulations, performed with SIMCOAL 2.0 (Laval and 
Excoffier, 2004) under a finite-site model and using the recombination rate 
of  the  tested  region  reported  in  HapMap  Phase  II  (Frazer  et  al.,  2007)   
and  the  deCODE  recombination  rate  given  in  the  UCSC  database 
(http://genome.ucsc.edu; Kong et al., 2002). Each of the 104 coalescent 
simulations was conditional on the observed sample size and the number of 
segregating sites observed for each gene. We corrected for the effects of 
demography on diversity patterns by considering two demographic models 
based on resequencing data for noncoding regions in a set of populations 
similar to those studied here (Voight et al., 2005; Laval et al., 2010). The main 
difference between these two demographic models is that the Laval’s model 
takes intercontinental population migration into account (Laval et al., 2010).
We  used  the  McDonald-Kreitman  Poisson  random  field  method 
(Sawyer and Hartl, 1992; Bustamante et al., 2005) to search for the effects   
of natural selection, taking into account both interspecies divergence and 
within-species polymorphism. For the detection of recent positive selection JEM Vol. 208, No. 13 
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